CXCL10 and non-small cell lung carcinoma: Ellsworth et al.18 reported that early stage non-small cell lung cancer patients undergoing hypofractionated SBRT (50–60 Gy in 10–20 fractions) have a more limited repertoire of circulating cytokines and less variability in cytokine levels at baseline and during treatment compared those receiving conventional fractionation RT, and that sCD40L is identified as one of three cytokines (CXCL10 and macrophage inflammatory protein-1 being the remaining two cytokines) that accounts for the majority of the variability in cytokine levels seen during lung SBRT.